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Background: A trial of neoadjuvant gemcitabine and pemetrexed
(GP) chemotherapy in patients with resectable non-small cell lung
cancer was conducted. The goal was to achieve a disease response
rate of 50% and to determine if the expression levels of genes
associated with GP metabolism are predictive of response.
Methods: Patients had staging with a computed tomography scan,
whole body F-18 fluorodeoxyglucose positron emission tomogra-
phy, and mediastinoscopy. Four biweekly cycles of GP were given.
Patients were restaged, and those with resectable stage IB-III disease
had thoracotomy. Fresh frozen tumor specimens were collected
before and after chemotherapy and the mRNA levels of 14 target
genes determined by real-time reverse transcription polymerase
chain reaction.
Results: Fifty-two patients started therapy. The radiographic disease
response rate was 35% (95% confidence interval 21.7–49.6%), and
the progression rate was 6%. Forty-six patients had a thoracotomy.
The complete tumor resection rate was 77% (40/52). There were no
perioperative deaths or deaths related to chemotherapy. Tumor
response to chemotherapy was inversely correlated with the level of
expression of RRM1 (p  0.001; regulatory subunit of ribonucle-
otide reductase) and TS (p  0.006; thymidylate synthase); i.e., the
reduction in tumor size was greater in those with low levels of
expression.
Conclusions: Neoadjuvant GP is well tolerated and produces an
objective response rate of 35%. Tumoral RRM1 and TS mRNA
levels are predictive of disease response and should be considered as
parameters for treatment selection in future trials with this regimen.
Key Words: Gemcitabine, Pemetrexed, Ribonucleotide reductase,
Thymidylate synthase, Non-small cell lung cancer.
(J Thorac Oncol. 2008;3: 1112–1118)
Incorporation of platinum-containing chemotherapy into themanagement of resectable non-small cell lung cancer
(NSCLC) has become the standard of care for patients with
metastatic disease in N1 or N2 lymph nodes.1–3 Neoadjuvant
treatment results in response rates of approximately 33 to
64%,4–7 and adjuvant therapy increases absolute overall sur-
vival (OS) by approximately 5 to 15%.1–3 However, the
approach of treating all patients with a platinum-containing
regimen may have reached a plateau in terms of efficacy. In
addition, there is significant toxicity associated with this
approach including a treatment-related mortality of approxi-
mately 1 to 2%.1,7
We had reported a response rate of 34% in patients with
operable stage I–III disease using a nonplatinum regimen
consisting of gemcitabine and vinorelbine in a phase II
neoadjuvant trial.8 The combination of gemcitabine and pem-
etrexed (GP) had yielded a response rate of 31% in patients
with previously untreated advanced-stage NSCLC if given on
a 3 weekly schedule, and efficacy seemed to be dependent on
the drug sequencing and scheduling.9 However, prior inves-
tigations of both drugs suggested that synergy as a result of
sequencing may vary from one in vitro system to another.10–12
In a phase I trial of G immediately followed by P given
biweekly, the maximum tolerated doses were 1500 and 500
mg/m2, respectively.13 The regimen produced a response rate
of 21% in untreated patients with advanced NSCLC, and it
was well tolerated.13
We conducted a single-institution trial of neoadjuvant
GP in patients with resectable NSCLC with the goal to
describe the clinical efficacy and tolerability of the chosen
regimen and to investigate the predictive utility of mRNA
expression of genes involved in the metabolism of these
drugs on therapeutic efficacy.
PATIENTS AND METHODS
Clinical Trial Characteristics and Study
Population
The study was approved by the University of South
Florida’s Institutional Review Board (ClinicalTrials.gov
NCT00226577). Clinical staging was determined by physical
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examination, computed tomography (CT) of the chest and
upper abdomen, whole body F-18 fluorodeoxyglucose
positron emission tomography, magnetic resonance imaging
of the brain, bronchoscopy, and mediastinoscopy. Histologic
confirmation of NSCLC; stage IB-IIIA and selected IIIB (two
lesions in one lobe, T4); age 18 years; a performance status
(PS) of 0 to 1; measurable disease by Response Evaluation
Criteria in Solid Tumors; and no prior therapy for lung cancer
were required for eligibility. These criteria were met by 52
patients.
Preoperative chemotherapy with G 1500 mg/m2 imme-
diately followed by P 500 mg/m2 was administered on days 1,
15, 29, and 43. Subsequent doses of chemotherapy were
delayed or reduced for toxicity if appropriate. Patients re-
ceived oral folate at a dose of 350 to 1000 g daily and
subcutaneous vitamin B12 at a dose of 1000 g every 9
weeks starting 1 week before chemotherapy. Dexamethasone
was given at a dose of 4 mg every 12 hours on the day before,
the day of, and the day after chemotherapy. All toxicities
were graded according to the common toxicity criteria (ver-
sion 3.0).
After chemotherapy, CT and positron emission tomog-
raphy scans were repeated between days 50 and 63. Radio-
graphic response was expressed as a continuous variable by
calculating the percentage of change in the sum of all greatest
tumor diameters comparing the posttreatment and pretreat-
ment CT scans (1 [sum postlesions/sum prelesions] 100)
and also by Response Evaluation Criteria in Solid Tumors as
best overall response.
Patients with resectable disease had thoracotomy be-
tween days 64 and 77. The recommended surgery was lobec-
tomy or pneumonectomy with mediastinal lymph node dis-
section. Segmentectomy or wedge resection was discouraged.
Patients with unresectable disease and those with incomplete
TABLE 1. mRNA Gene Expression Characteristics and Association with Radiographic Disease Response
Gene Name Probe set ID N Min. Max. Median Mean
Spearman’s
Rho p
Clinical Response 49 95% (increase) 100% (decrease) 19% 19%
RRM1 Regulatory subunit
of ribonucleotide
reductase
–a 35 0.37 7.93 1.68 2.72 0.649 0.001
RRM2a Catalytic subunit of
ribonucleotide
reductase
Hs00367247-m1 32 0.00 5.42 0.90 1.38 0.017 0.924
RRM2b P53-inducible
catalytic subunit
of ribonucleotide
reductase
Hs00153082-m1 32 0.00 12.24 1.34 1.99 0.276 0.125
DCK Deoxycytidine
kinase
Hs00176127-m1 32 0.46 40.39 3.82 5.52 0.130 0.476
CDA Cytidine deaminase Hs00156401-m1 32 0.00 118.66 2.42 10.27 0.028 0.878
ENT1 (SLC29A1) Equilibration
sensitive
nucleoside
transporter 1
Hs00191940-m1 32 0.00 21.42 1.30 2.18 0.162 0.374
5-NT (NT5C1A) Cytosolic
5-nucleotidase
Hs00261369-m1 32 0.00 170843.81 0.00 10.89 0.081 0.657
TS Thymidylate
synthase
Hs00426591-m1 35 0.32 18.31 3.39 4.46 0.454 0.006
DHFR Dihydrofolate
reductase
Hs00758822-s1 32 0.00 9.83 0.85 1.29 0.166 0.362
GARFT Phosphoribosylgly
cinamide formyl
transferase
Hs00531926-m1 32 0.17 21.93 1.19 2.28 0.002 0.988
FPGS Folylpolyglutamate
synthase
Hs00191956-m1 32 0.36 32.75 2.23 3.50 0.222 0.220
ENT2 (SLC29A2) Equilibration
sensitive
nucleoside
transporter 2
Hs00155426-m1 32 0.11 41.30 5.16 7.76 0.125 0.494
RFC1 (SLC19A1) Reduced folate
carrier
Hs00161870-m1 32 0.01 33.47 0.12 2.23 0.096 0.600
-GH Gamma-glutamyl
hydrolase
Hs00608257-m1 32 0.07 33.52 2.47 5.75 0.015 0.934
a 5-FAM-TTTGC TCTTT GGATT CCGGA TCTCT TCA-TAMRA-3.
Min., minimum; max., maximum.
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resections were treated at the discretion of their physician. All
patients were followed at 3 month intervals for 2 years and
then every 6 months with a CT scan.
Molecular Investigations
Tumor samples were collected before and after ther-
apy as frozen specimens. The standard operating procedure
for collection included a recording of the time from biopsy
or resection to freezing, and the time elapsed was 30
minutes or less in all cases. Frozen specimens were em-
bedded in optimal cutting temperature medium and cut in
5 to 7 m sections.
Tumor cells were collected by laser capture microdissec-
tion using the Arcturus system. Total RNA was extracted using
a commercial method (Arcturus, Mountain View, CA), and
cDNA was generated with oligo-dT and random primers. Real-
time quantitative polymerase chain reaction analysis was per-
formed in triplicate per sample (7900HT, ABI, Foster City, CA).
The probe and primers for RRM1 were those previously de-
scribed.14 Commercially available primers and probes were used
for expression analysis of all other target genes (Table 1). The
relative amount of RRM1 and TS mRNA in a sample was
determined by comparing the threshold cycle with a standard
curve as described.14 For the remaining genes, relative quanti-
fication was performed by comparison of the test samples to a
single calibrator sample in a fluidic card assay. Negative controls
without a cDNA template were included in all experiments.
TABLE 2. Patient Characteristics, Disease Response, and Survival
Radiographic
Response Ratea
Pathologic
Response Rateb
Median Overall
Survival
Median Disease-Free
Survivalc
All patients N  52 35% (17/49) 30% (13/43) 27.8 mo 33.7 mo
Age (yr), median (range) 67 (41–83)
67 n  26 38% (9/24) 25% (6/24) 27.0 mo 21.1 mo
67 n  26 32% (8/25) 33% (7/21) 27.8 mo p  0.99 21.0 mo p  0.45
Gender
Women n  26 32% (8/25) 27% (6/22) 27.8 mo 21.1 mo
Men n  26 38% (9/25) 33% (7/21) 27.4 mo p  0.80 33.7 mo p  0.75
Performance status
Zero n  31 36% (10/28) 36% (10/28) 27.8 mo 33.7 mo
One n  21 33% (7/21) 20% (3/15) 16.8 mo p  0.006 11.6 mo p  0.96
Weight lossd
Absent n  47 34% (15/44) 31% (12/39) 27.4 mo 33.7 mo
Present n  5 40% (2/5) 25% (1/4) 16.1 mo p  0.03 9.1 mo p  0.31
Smoking statuse
Active n  23 30% (6/20) 21% (4/19) 25.0 mo 21.0 mo
Quit (1 yr) n  27 41% (11/27) 36% (8/22) 27.8 mo p  0.42 20.7 mo p  0.37
Never smoker n  2 NA (0/2) NA (1/2)
Histopathologyf
Squamous n  19 39% (7/18) 22% (4/18) 27.8 mo 20.7 mo
Nonsquamous n  33 32% (10/31) 36% (9/25) 27.4 mo p  0.93 21.1 mo p  0.73
Stage
I n  16 31% (5/16) 27% (4/15) 27.8 mo 20.7 mo
II n  18 38% (6/16) 29% (4/14) 19.8 mo p  0.83 20.8 mo p  0.33
IIIg n  18 35% (6/17) 36% (5/14) 25.0 mo 21.1 mo
Tumor resection
Complete n  40 37% (14/38) 33% (13/39) 27.8 mo 33.7 mo
Incomp./not done n  12 27% (3/11) 0% (0/4) 12.8 mo p  0.02 NA p  NA
Response to chemotherapyh
CR/PR n  17 NA (17/17) 38% (6/16) 27.4 mo
SD n  29 NA (0/29) 24% (6/25) 27.8 mo p  0.71 18.2 mo
PD n  3 NA (0/3) 0% (0/1) 28.0 mo 33.7 mo p  0.39
a Not assessed in three patients.
b Not assessed in nine patients.
c In the 40 patients with complete tumor resection.
d Equal to or greater than 5% during the 3 months before diagnosis.
e A life-time never smoker was defined as a person that had smoked less than a total of 100 cigarettes.
f Twenty-one patients had adenocarcinoma including five with bronchioloalveolar features, 12 had other NSCLC subtypes including two adenosquamous carcinomas, two mixed
adenocarcinoma and squamous carcinoma, and one large cell carcinoma with suggestive neuroendocrine features.
g Two T4N0, T4 because of two separate tumor nodules in a single lobe of the lung.
h The pathologic disease response categories pPR and pNR were not significantly associated with OS (hazard ratio for pPR versus pNR  1.1, p  0.90) or DFS (hazard ratio
for pPR versus pNR  0.87, p  0.78).
NA, not applicable; incomp., incomplete; CR, complete remission; PR, partial remission; SD, stable disease; PD, partial disease.
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Statistical Considerations
Correlation coefficients between the expression of 14
genes, seven each potentially related to G and P efficacy, and
the continuous variable tumor response were calculated ac-
cording to Spearman.15 The statistical significance level was
adjusted for multiple analyses according to Bonferroni to a p
value of 0.0036; i.e., 0.05 divided by 14, because 14 inde-
pendent or dependent genes were tested on the same data-
set.16 The two-sided pooled t test or Wilcoxon Rank Sum test
was used to test for significance between dichotomous vari-
ables and gene expression. The Kruskal Wallis test was used
to test for significance between noncontinuous variables with
more than two values and gene expression. Kaplan-Meier
survival estimates were generated to describe the disease-free
survival (DFS) and OS. OS was estimated from the date of
diagnosis to the date of death or last observation, and DFS
was estimated from the date of surgery to the date of recur-
rence, death, or last observation. Patients without an event
were censored as of the date of last observation.
RESULTS
Induction Chemotherapy and Toxicity
A total of 52 eligible patients, 26 men and 26 women,
between the ages 41 and 83 years (median 67 years), received
at least one dose of chemotherapy. They were enrolled
between April 2004 and April 2006, and their characteristics
are described in Table 2. Forty-two patients received all
planned chemotherapy on time and without dose reduction.
Three patients had dose delays without dose reductions. The
reasons were a grade 3 lower extremity cellulitis, a grade 2
thrombocytopenia, and a grade 3 liver enzyme elevation.
Seven patients had less than the intended four biweekly
FIGURE 1. Water fall plots of radiographic disease response
and mRNA gene expression.
FIGURE 2. Kaplan-Meier overall and disease-free survival
(OS and DFS) estimates. The black curve denotes OS and
the red curve DFS. Tick marks indicate censored cases.
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therapies. Three patients had only the first cycle because of
grade 3 neutropenic fever with renal failure (stage T2N2M0),
a grade 3 febrile drug reaction, and one patient requested
immediate surgery without having experienced treatment-
related side effects. Three patients only had cycles 1 and 2.
The reasons were a grade 3 lower extremity phlebitis in one
patient and grade 3 fatigue in two. One patient (stage
T2N2M0) died after cycle 3 from pneumonitis of a likely
viral etiology; however, a possibly treatment-related etiology
could not be excluded.
Radiographic Response to Chemotherapy
A radiographic response evaluation was possible in 49
patients. The best overall response was a complete remission
(CR) in 1 (2%; 95% confidence interval [CI] 0.1–10.9%)
patient; it was a partial remission (PR) in 16 (33%; 95% CI
20.0–47.5%), stable disease in 29 (59%; 95% CI 44.2–
73.0%), and progressive disease in 3 (6%; 95% CI 1.3–
16.9%) patients. The response ranged from a 95% increase to
a 100% decrease in the size of measurable lesions (Figure
1A). There were no statistically significant associations be-
tween radiographic disease response and the clinical param-
eters age (p  0.62), gender (p  0.96), PS (p  0.94),
weight loss (p  0.88), smoking status (p  0.85), tumor
histology (p  0.95), and stage (p  0.31) (Table 2).
Pathologic Response to Chemotherapy
A pathologic response evaluation was performed by
determination of the proportion of necrotic and/or fibrotic
material on light microscopical evaluation of surgical resec-
tion specimens stained with hematoxylin and eosin. This was
possible in 43 patients, and it ranged from 0 to 90%. None of
the patients had a pathologic CR (95% necrosis/fibrosis),
13 (30%) had a pathologic PR (50–94% necrosis/fibrosis),
and 30 (70%) had no pathologic response. There were no
statistically significant associations between pathologic dis-
ease response and the clinical parameters age (p  0.39),
gender (p  0.65), PS (p  0.18), weight loss (p  0.69),
smoking status (p  0.96), tumor histology (p  0.43), and
stage (p  0.66). Although there was a correlation between
radiographic and pathologic response (Spearman’s rho 
0.23); i.e., better clinical response was associated with a
higher proportion of necrosis and fibrosis, it was not statisti-
cally significant (p  0.14).
Surgical Treatment
A thoracotomy was performed in 46 patients, and it
resulted in a complete resection in 40 patients. Thirty-two
patients had a lobectomy, two had a bilobectomy, eight had a
pneumonectomy, two had a wedge resection, and two had no
tumor resection. At the surgical resection, 17 patients were
down-staged, 17 had no change, and 12 were up-staged
compared with the initial staging. One patient died 2.7
months after a complete right upper and middle lobectomy
for a T2N1 squamous cell carcinoma of a bronchopleural
fistula.
Recurrence and Survival
As of the index date June 20, 2008, 32 patients were
alive (20 without evidence for disease, seven with recurrence,
three with incomplete and two without resection), 14 had died
of lung cancer (10 with recurrence, one with incomplete and
three without resection), and six had died of causes other than
FIGURE 3. Pretreatment and posttreatment mRNA levels of
the genes RRM1 and TS in 10 patients.
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lung cancer (four from cardiovascular disease). The median
follow-up for the 32 living patients was 36.5 months, and it
was 30.7 months for the 20 patients with a complete resection
and no event. In the 17 patients with disease recurrence after
a complete resection, the first site of recurrence was within
the region of resected disease in two patients, and it was in
previously uninvolved hilar or mediastinal lymph nodes in
four patients and in distant sites in 11 patients (five brain,
three bone, two lung, one adrenal). In one patient with local
recurrence, a resection was successful; however, the disease
recurred in the brain.
The median OS was more than 27.8 months, and the
median DFS for patients with a complete surgical resection
was 33.7 months (Figure 2). The 12-month and 24-month OS
rates were 84.6% (95% CI 71.6–92.0%) and 71.0% (95% CI
56.5–81.4%), and the corresponding DFS rates were 67.5%
(95% CI 50.7–79.7%) and 51.3% (95% CI 34.6–66.2%),
respectively. The radiographic or pathologic response to
chemotherapy was not significantly associated with OS or
DFS (Table 2).
Pharmacogenomic Variables Predictive of
Disease Response
Pretreatment tumor specimens of sufficient quantity
and quality for gene expression analysis by real-time reverse
transcription polymerase chain reaction were available on 10
and posttreatment specimens on 35 patients. We evaluated if
GP therapy would alter the mRNA levels of RRM1 and TS.
There was a significant correlation between pretreatment and
posttreatment levels for both genes (Spearman’s rho 0.786,
p  0.025) suggesting that postchemotherapy gene expres-
sion levels are representative of pretreatment levels. How-
ever, we observed that gene expression levels seem to in-
crease with treatment (Figure 3). All subsequent analyses
were performed on the 35 posttreatment specimens. The
ranges of expression and other marker characteristics for all
14 genes are summarized in Table 1. The mRNA levels of
RRM1 were significantly correlated with disease response
(rho  0.649, p  0.001); i.e., low levels were predictive
of tumor size reduction and high levels of tumor growth
(Figure 1B). Of the 18 patients with RRM1 expression equal
to or below the median of 1.68, 10 had a PR or CR, whereas
only 2 of the 17 with high RRM1 expression responded. The
mRNA levels of TS were likewise correlated with disease
response (rho  0.454, p  0.006) (Figure 1C); however,
after using a Bonferroni adjustment for multiplicity of data
analysis, the p value was above the level of 0.0036. Of the 18
patients with TS expression equal to or below the median of
3.40, seven had a PR or CR, whereas 5 of the 17 with high TS
expression responded. The expression levels of all other
genes were not significantly correlated with disease response
(Figures 1D, E).
There was no significant difference in OS or DFS
between patients with high versus low RRM1 or TS mRNA
expression when dichotomized by the gene expression medi-
ans of 1.68 for RRM1 or 3.39 for TS (Table 3).
DISCUSSION
A major goal of current research efforts in NSCLC is to
increase the efficacy of perioperative systemic therapy in
patients with a complete surgical resection through incorpo-
ration of molecular parameters into clinical therapeutic deci-
sions. Although most of the data demonstrating efficacy of
perioperative systemic therapy has been generated with post-
operative treatments, there is presently no evidence to suggest
that preoperative therapy is less efficacious. Assuming that
both approaches result in similar clinical outcomes, preoper-
ative systemic therapy is substantially better suited for the
prospective evaluation of the increasing number of molecular
markers on treatment effects. In particular, drug targets can
be studied pretherapy and posttherapy, disease response can
be used as the primary outcomes variable, and dynamic
parameters that may influence drug efficacy can be studied.
We investigated the preoperative efficacy of a nonplati-
num doublet, namely GP, in patients with surgically resect-
able NSCLC. The rationale for this combination was that
both agents are antimetabolites with relatively well known
mechanisms of action, both are well tolerated, both are
efficacious and already integrated into patient care, and prior
in vitro studies had suggested cytotoxic synergy between
them. Platinum-based postoperative chemotherapy improves
5-year survival by 5 to 15% in patients with completely
resected stage II and III disease.1–3 However, there is sub-
stantial toxicity associated with this therapy,1–3 and therapeu-
tic benefit seems to be restricted to patients with low tumoral
excision repair cross-complimentary group 1 (ERCC1) lev-
els.17 Prior randomized phase III neoadjuvant studies that
used platinum-based chemotherapy had reported response
rates of 33%,5 41%,7 49%,6 and 64%.4 Approximately 75% of
patients received all planned chemotherapy and the chemo-
therapy-related mortality was approximately 2%. These re-
sponse rates seem higher than our response rate of 35%;
however, 18/52 patients in our study had stage III disease,
whereas two of the referenced trials did not include stage III
patients,5,7 and the proportion of stage III patients in the other
two trials was 7%6 and 47%,4 respectively. In two earlier
randomized neoadjuvant trials with platinum-based therapy
in patients with stage III disease, the reported response rates
were 53% (16/30)18 and 35% (9/26).19 We had a priori set our
TABLE 3. Median Overall and Disease-Free Survival by RRM1 and TS mRNA Expression
Median OS Log-rank p Median DFS Log-rank p
RRM1 high (1.68) 27.8 mo 0.083 20.7 mo 0.146
RRM1 low (1.68) 27.4 mo 21.0 mo
TS high (3.39) 27.8 mo 0.272 20.7 mo 0.187
TS low (3.39) 27.0 mo 21.0 mo
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expected response rate at 50%; a goal, which we did not
achieve. We therefore conclude that the combination of GP is
unlikely to be superior to platinum-containing doublets if
given to an unselected group of patients with resectable
NSCLC.
Eighty-seven percent (45/52) of patients in our trial
received the planned four cycles of therapy. Five patients had
less than four cycles because of treatment-related grade 3
toxicities, and of these, four had surgery with a complete
resection. One patient died before surgery from a presumed
viral pneumonitis. We conclude that the combination of GP is
well tolerated and is deliverable as four biweekly treatments
to a proportion of patients that is at least equal to the
proportion of patients that can receive a platinum-containing
doublet.
Our pharmacogenomic studies indicate that the magni-
tude of tumor response to GP is associated with tumoral
expression of the genes RRM1 and TS. Patients whose tumors
express these genes at low levels are more likely to experi-
ence a reduction in tumor size compared with those with high
levels of gene expression. This association was significant for
the gene RRM1, but failed to reach the significance level of
0.0036 for TS. Because we evaluated a total of 14 genes in
these patients, we adjusted the significance level according to
Bonferroni. This is a conservative approach to adjustment for
multiplicity of data analysis, and most correlative investiga-
tions are conducted under less stringent conditions. It is thus
our opinion, that the correlation coefficient of () 0.454 seen
for the association between TS expression and response to
treatment is remarkable and requires further exploration.
In summary, the clinical correlative investigations de-
scribed extend the previously known relationship between
RRM1 expression and gemcitabine efficacy to the combina-
tion of GP. They also provide reasonable evidence for an
association between TS expression and efficacy of this com-
bination. In an unselected group of patients with resectable
NSCLC, GP provide an objective radiographic response
rate of 35% with good tolerability. We conclude that
further investigation of this drug combination is warranted
with selection of patients based on the expression of RRM1
and TS.
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